SLC22A6 and Ascites: In vitro data indicate that furosemide, which can be coadministered with spironolactone to treat ascites, is a weak inhibitor of the renal transporters OAT1 and OAT3, although it is predicted to have a clinically insignificant effect on the OAT1 and OAT3 substrate, tenofovir.54